Get started
Author

Ricardo Bellott

Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38
2004 · V CHARASSON, R BELLOTT, et al. · Clinical Pharmacology & Therapeutics · 66
Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia
2000 · Ricardo Bellott, Anne Auvrignon, et al. · Cancer Chemotherapy and Pharmacology · 63
Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val Gene Polymorphisms In Colorectal Cancer Patients: Relationships with Treatment Outcome
2007 · Valérie Le Morvan, Denis Smith, et al. · Pharmacogenomics · 61
A chemotherapy-associated senescence bystander effect in breast cancer cells
2008 · Xu Di, Andrew Taylor Bright, et al. · Cancer Biology & Therapy · 57
PDF
A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours
2006 · On behalf of the United Kingdom Children's Cancer Study Group (UKCCSG) New Agents and Société Française d'Oncologie Pédiatrique (SFOP) Pharmacology Group, S Lowis, et al. · British Journal of Cancer · 55
PDF
Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome
2001 · Ricardo Bellott, Paul Pouna, et al. · Journal of Chromatography B Biomedical Sciences and Applications · 38
Relationships Between Genetic Polymorphisms and Anticancer Drug Cytotoxicity Vis-à-Vis the NCI-60 Panel
2006 · Valérie Le Morvan, Ricardo Bellott, et al. · Pharmacogenomics · 34
Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene
2007 · Ricardo Bellott, Valérie Le Morvan, et al. · Cancer Chemotherapy and Pharmacology · 24
Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial
2014 · V Le Morvan, S Litière, et al. · The Pharmacogenomics Journal · 15
A phase II study for the evaluation of quinine as a modulator of multidrug resistance in non-Hodgkin’s lymphoma
2006 · Pierre Soubeyran, Amine Masmoudi, et al. · European Journal of Cancer · 4
Evidence for an alpha 2-macroglobulin with complement-inhibiting activity in rat serum.
1991 · R Bellott, A Bon, et al. · Europe PMC (PubMed Central) · 3
Characterization of one α2-macroglobulin with anticomplementary activity from pregnant women
1990 · Jacques Lestage, Ricardo Bellott, et al. · Human Reproduction · 3
Abstract 1871: Role of CYP1B1 gene polymorphisms in anticancer drug cytotoxicity as studied on isogenic cell lines
2012 · Valérie Le Morvan, Elodie Richard, et al. · Cancer Research · 2
Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI60 panel
2006 · Valerie Lemorvan, Ricardo Bellott, et al. · Cancer Research · 2
Identification of SNPs Associated to Response of Breast Cancer Patients to Neo-Adjuvant Chemotherapy in the EORTC-10994 / BIG1-00 Randomised Phase III Trial
2013 · J. Robert, V. Le Morvan, et al. · Annals of Oncology
PDF
Pharmacog�n�tique de l?irinot�can: la carboxylest�rase 2
2005 · V. Charasson, R. Bellott, et al. · ONCOLOGIE
Reversion of Chemoresistance in Aggressive Lymphoma by Quinine. A Phase II Trial.
2004 · Pierre Soubeyran, Amine Masmoudi, et al. · Blood
Mise en évidence et purification d'une sous-forme d'alpha-2macroglobuline sérique à activité modulatrice sur le complément : modèle salamandre, rat et humain
1991 · Ricardo Bellott Araya
Chemical and physiological characterizations of subform of Λ2-macroglobulin with immunomodulatory properties in rat
1989 · R. Bellott, A. Bon, et al. · Journal of Reproductive Immunology
Evidence of subform of the Λ2-macroglobulin with immunodulatory properties in pregnant women
1989 · P. Chateaureynaud, R. Bellott, et al. · Journal of Reproductive Immunology
Works count: 21
Citation count: 427
H-index: 9
I10-index: 9
Year
Topic
Type